| Drug Name |
Guanfacine |
| Drug ID |
BADD_D01046 |
| Description |
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841]
Guanfacine was granted FDA approval on 27 October 1986.[L11274] |
| Indications and Usage |
For use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C02AC02 |
| DrugBank ID |
DB01018
|
| KEGG ID |
D08031
|
| MeSH ID |
D016316
|
| PubChem ID |
3519
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
63304-927; 0591-0453; 63629-8203; 50090-4119; 70518-2771; 63304-924; 42291-326; 54092-519; 60429-961; 70518-1371; 0591-0444; 63304-925; 70518-0793; 54092-520; 63187-302; 60505-3927; 60429-960; 24979-536; 60429-963; 24658-731; 54092-517; 71205-945; 54092-515; 60429-962; 42806-048; 16714-193; 16714-190; 63629-1105; 42291-324; 42806-296; 24658-730; 63629-8161; 0228-2850; 42291-327; 24979-538; 16714-192; 63304-926; 0228-2853; 60505-3930; 16714-191; 60505-3928; 68094-019; 0228-2855; 50268-374; 24979-534; 65162-711; 0904-7140; 42291-325; 65162-713; 60505-3929; 71205-946; 70518-1369; 63629-7138; 24979-533; 71205-947; 54092-513; 0228-2851; 71205-944 |
| Synonyms |
Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic |
